Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | CSK | P41240 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004840 | 0.81 | PKM (0.53) | SMN1; SMN2ALDH1A1FFAR1ENPP2CSK | |
| SCHEMBL8746034 | 0.78 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1KMT2AFFAR1STAT3 | |
| SCHEMBL7835806 | 0.78 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1KMT2AFFAR1STAT3 | |
| SCHEMBL11212870 | 0.76 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KMT2AKDM4E | |
| SCHEMBL11212921 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL1395735 | 0.76 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KMT2ATSHR | |
| SCHEMBL11217371 | 0.76 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL1170312 | 0.75 | FFAR1 (0.68) | SMN1; SMN2ALDH1A1KMT2AFFAR1STAT3 | |
| SCHEMBL11214702 | 0.74 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1KMT2AFFAR1CA1 | |
| SCHEMBL13476511 | 0.74 | LMNA (0.47) | SMN1; SMN2ALDH1A1KMT2AKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | SMN1; SMN2 4188/4885ALDH1A1 1087/4885KMT2A 3867/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | SMN1; SMN2 4188/4885ALDH1A1 1087/4885KMT2A 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.